USRE40023E1 - Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use - Google Patents
Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use Download PDFInfo
- Publication number
- USRE40023E1 USRE40023E1 US11/375,704 US37570406A USRE40023E US RE40023 E1 USRE40023 E1 US RE40023E1 US 37570406 A US37570406 A US 37570406A US RE40023 E USRE40023 E US RE40023E
- Authority
- US
- United States
- Prior art keywords
- weight
- composition
- lyophilized
- lactobacillus
- total
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title description 9
- 235000005911 diet Nutrition 0.000 title description 5
- 230000000378 dietary effect Effects 0.000 title description 5
- 239000000203 mixture Substances 0.000 claims abstract description 106
- 238000000034 method Methods 0.000 claims abstract description 34
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 29
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 22
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 6
- 208000010643 digestive system disease Diseases 0.000 claims abstract 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims abstract 4
- 230000028993 immune response Effects 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 30
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 19
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 19
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 19
- 244000199866 Lactobacillus casei Species 0.000 claims description 18
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 18
- 229940017800 lactobacillus casei Drugs 0.000 claims description 18
- 239000008101 lactose Substances 0.000 claims description 18
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 17
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 17
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 15
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 15
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 14
- 241001608472 Bifidobacterium longum Species 0.000 claims description 13
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 12
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims description 12
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 12
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 11
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 11
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 10
- 229920002774 Maltodextrin Polymers 0.000 claims description 10
- 239000005913 Maltodextrin Substances 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 229940035034 maltodextrin Drugs 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 229920002261 Corn starch Polymers 0.000 claims description 9
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 9
- 235000019759 Maize starch Nutrition 0.000 claims description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- 239000008121 dextrose Substances 0.000 claims description 9
- 229960002737 fructose Drugs 0.000 claims description 9
- 241000194031 Enterococcus faecium Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 230000001800 adrenalinergic effect Effects 0.000 claims description 2
- 239000000464 adrenergic agent Substances 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- 239000000739 antihistaminic agent Substances 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims description 2
- 229940064004 antiseptic throat preparations Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002443 hepatoprotective effect Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 230000002402 anti-lipaemic effect Effects 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 241000186660 Lactobacillus Species 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 9
- 238000000855 fermentation Methods 0.000 description 21
- 230000004151 fermentation Effects 0.000 description 21
- 238000004108 freeze drying Methods 0.000 description 14
- 229940041514 candida albicans extract Drugs 0.000 description 13
- 239000012138 yeast extract Substances 0.000 description 13
- 239000012466 permeate Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 239000008103 glucose Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- 238000006386 neutralization reaction Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-O azanium;hydron;hydroxide Chemical compound [NH4+].O VHUUQVKOLVNVRT-UHFFFAOYSA-O 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 230000001012 protector Effects 0.000 description 6
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 5
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000020183 skimmed milk Nutrition 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 235000013618 yogurt Nutrition 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020961 Hypocholesterolaemia Diseases 0.000 description 2
- 240000002129 Malva sylvestris Species 0.000 description 2
- 235000006770 Malva sylvestris Nutrition 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000001471 micro-filtration Methods 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000186334 Propionibacterium freudenreichii subsp. shermanii Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001861 endoscopic biopsy Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- -1 paraffines Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
Definitions
- the present invention relates to dietary and pharmaceutical compositions useful for dietary or certain pharmaceutical indications, said composition containing lyophilized, lactic bacteria. Said compositions, being useful for prophylaxis or treatment of gastrointestinal disorders, or for treatment of hypocholesterolemia.
- Takano et al. U.S. Pat. No. 4,913,913, describes a method for preparing a bifidobacteria-containing fermented milk, in which Lactobacilius casei and Bifidobacterium longum are cultivated in admixture or are mixed after being separately cultivated, and thus a bifidobacteria-containing lactic acid bacteria-fermented milk with an elevated survival rate of Bifidobacterium longum is obtained.
- composition comprising at least two lactic acid bacteria strains allows improved therapeutical results to be achieved of a kind never previously attained by prior art compositions, provided that the concentration of each of two lactic bacteria strains exceeds 10 11 viable lactic bacteria/gram of composition.
- composition of the present invention can be used in combination with any of a variety of compatible drugs.
- the present composition can be used to antagonize the onset of diarrhea, constipation, hypercholesteremia, endotoxin absorption or production of endogenous toxic substances.
- compositions of the present invention comprise as essential active ingredients: (a) from 10 to 95% by weight of total composition of lyophilized lactic bacterium Streptococcus thermophilus, and (b) from 90 to 5% by weight of total composition of at least one further lyophilized lactic bacterium selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei.
- An excipient in an amount of from 1 to 10% by weight of total components can be added, said amounts being all based on the total weight of the composition.
- the composition can be used in combination with a compatible pharmaceutical in an amount of from 1 to 20% by weight based on the total weight of the composition.
- the viable bacteria concentration be at least 1 ⁇ 10 11 for (a) and 1 ⁇ 10 11 for (b) per gram of the composition.
- the viable bacteria concentration of both (a) and (b) should be used between 1 ⁇ 10 11 and 1 ⁇ 10 13 per gram of the composition.
- compositions of the invention can be prepared with methods well-known to those skilled in dairy technology, enabling the presence of viable bacteria at concentrations ranging between 1 ⁇ 10 11 and 1 ⁇ 10 13 bacteria per gram of the composition.
- the composition should also contain from 85 to 5% by weight of one or more lyophilized lactic bacteria selected from bifidobacteria (preferably a mixture of lyophilized Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium infantis, ratio of 1:1:1 by weight) at a concentration ranging between 1 ⁇ 10 9 and 1 ⁇ 10 12 viable bacteria per gram of the composition, lyophilized Lactobacillus acidophilus at a concentration of from 1 ⁇ 10 9 to 1 ⁇ 10 12 viable bacteria per gram of the composition, lyophilized lactobacillus delbruekii sub-species bulgaricus at a concentration of from 1 ⁇ 10 9 to 1 ⁇ 10 12 viable bacteria per gram of the composition, and lyophilized Streptococcus faecium at a concentration of from 1 ⁇ 10 9 to 1 ⁇ 10 12 bacteria per gram of the composition, optionally with 1 to 10% of an excipient and 1 to
- a particularly preferred composition according to the present invention contains: a) 31% by weight of lyophilized Streptococcus thermophilus, 7 ⁇ 10 11 ; b) 7% by weight of lyophilized Lactobacillus casei, 1 ⁇ 10 11 ; c) 8% by weight of lyophilized Lactobacillus plantarum, 1 ⁇ 10 11 ; d) 7% by weight of lyophilized Lactobacillus acidophilus, 2 ⁇ 10 10 ; e) 8% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus, 3 ⁇ 10 9 ; f) 27% by weight of lyophilized bifidobacteria, 38 ⁇ 10 10 ; and g) 12% by weight of an excipient, wherein all the amounts are based on the total weight of the composition and Bifidobacterium Bifidum, Bifidobacterium longum and Bifidobacterium infantis.
- compositions of the invention may contain usual excipients as are conventionally used for preparing pharmaceutical compositions in which normally the ratio of the active ingredient to the excipient will range between 1:10 and 99:90.
- compositions of the invention can be made in conventional pharmaceutical forms, such as for example tablets, coated tablets, capsules, packets, solutions, sachets, suspensions, emulsions, suppositories, pellets, syrups, vaginal suppositories, and are prepared in the usual m manner by mixing active ingredients in the mentioned amounts, eventually adding excipients and/or carriers, adjuvants and/or dispersing agents.
- Water may be used as the diluent.
- Organic solvents can be used in the form of adjuvants.
- Adjuvants can be for example, non-toxic organic solvents such as paraffines, vegetable oils (peanut oil or sesame oil), glycerine, glycols (propylene glycol, polyethylene glycol), solid carriers such as for example natural mineral flours (kaolin, talc), synthetic mineral flours (silicates for example), sugar (cane sugar for example), emulsifiers (alkylsulfonates or arylsulfonates and the like), dispersants (lignin, methylcellulose, starch and polyvinylpyrrolidone, for example) and lubricants (magnesium stearate, talc, stearic acid, sodium laurylsolfonate, for example).
- Preferred excipients for the composition of the invention are maltodextrin, microcrystalline cellulose, maize starch, levulose, lactose and dextrose.
- the administration takes place in the usual manner, preferably by oral route.
- pharmaceutical forms adapted to this end can obtain, in addition to usual excipients, also additives such as sodium citrate, calcium carbonate, calcium dihydrogen phosphate, together with several additional substances such as starch, gelatin and the like.
- additional substances such as starch, gelatin and the like.
- compatible colouring agents of flavoring substances may be added.
- the compositions may contain such compatible pharmaceuticals as anticholinergies, antihistamines, analgesics, adrenergics, antiinflammatories, antiseptics, hepatoprotective agents, or antilipemic drugs, in amounts of from 1 to 20% by weight, based on the total weight of the composition.
- compatible pharmaceuticals as anticholinergies, antihistamines, analgesics, adrenergics, antiinflammatories, antiseptics, hepatoprotective agents, or antilipemic drugs.
- the formulation of the preparation was in form of sachets, each containing 3 g of the composition. All the following studies were carried out in human health volunteers and in patients enrolled after informed consent according to the Helsinki declaration. Medical and laboratory controls were done by physicians aware of the good usual clinical practice (GPC) as stated by the European Economic Community (EEC). Statistical analysis was carried out by a statistician, not directly involved in the study. T0, T1, T2, and T3 refer respectively to pre-treatment, after one, two and three weeks of treatment.
- the individual strains maintained in a lyophilized and frozen form have been grown in synthetic media specific for each species.
- the fundamental component of the culture medium is permeate obtained by ultrafiltration of serum or milk, to which minimal amounts of biological activators are added depending on the species. After sterilization, the culture medium is inoculated with a strain per species or 1 to 3 strains belonging to the same genotype. Cultures have been incubated upon determination of optimal parameters for each strain: temperature, time, pH values and stirring.
- the mother has been prepared by inoculating the strain in a medium consisting of 5% of permeate +1% of yeast extract and incubated at 44° C. over 3 hours.
- the mother has been prepared by inoculating the strains in a medium consisting of 10% of powdered skimmed milk +0.5% of glucose +1% of yeast extract and incubated at 38° C. over 15 hours.
- Lyophilization Lyophilizer Edwards MINI - FAST 3400 Lyophilization protector a solution of powdered skimmed milk+yeast extract+lactose+sodium maleate has been prepared.
- Lyophilization Lyophilizer Edwards MINI - FAST 3400 Lyophilization protector a solution of lactose and anhydrous mixture consisting of powdered skimmed milk+yeast extract+lactose+sodium maleate+Tween (Registered Trademark) 80. Results: the number of microorganisms during the different process steps is reproduced in the following Table:
- Lactobacillus delbrueckii sub-species bulgaricus (ATCC 7994)
- Lyophilization Lyophilizer Edwards MINI - FAST 3400 Lyophilization protector a solution of lactose and anhydrous mixture consisting of powdered skimmed milk+yeast extract+lactose+sodium glutamate+Tween (Registered Trademark) 80. Results: the number of micoorganisms during the different process steps is reproduced in the following Table:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A pharmaceutical composition containing several different bacteria including Streptococcus thermophilus, Lactobacilli and Bifidobacteria is disclosed. The bacteria are present in the composition at a total concentration of 1×1011 to 1×1013 per gram. Further, methods of using the pharmaceutical are disclosed which include treatment of a gastrointestinal disorder and hypercholestermia. Also a method for modulating a host's immune response is disclosed.
Description
This application is a reissue of application Ser. No. 08/448,787, filed May 24, 1995, now U.S. Pat. No. 5,716,615, which is a continuation of application Ser. No. 08/117,751, filed on Sep. 8, 1993, now abandoned, which is a continuation-in-part of application Ser. No. 07/983,839, filed Dec. 1, 1992, now abandoned.
The present invention relates to dietary and pharmaceutical compositions useful for dietary or certain pharmaceutical indications, said composition containing lyophilized, lactic bacteria. Said compositions, being useful for prophylaxis or treatment of gastrointestinal disorders, or for treatment of hypocholesterolemia.
In Bifidobacteria Microflora, Vol. 3(1), 29-33, 1984, the beneficial effect of administering Bifidobacterium to patients suffering from leukemia is described. In FEMS Microbiology Reviews 46 (1987), 343-356, the therapeutical function of lactobacilli is disclosed, while Nobuo Suegara et al., Microecology and Therapy, Vol. 15, 271-280 (1985) state that oral administration of S. faecalis KAWAI greatly improves the lipid metabolism in human beings and animals. From Microecology and Therapy, Vol. 14, 109-126 (1984) the effect of streptococcus cell extracts on hyperlipemia in rats, rabbits and human beings is known. Other references describing the beneficial action of lactobacilli or other strains of activated lactobacilli are for example Bifidobacteria Microflora 1, 3-24, 1982 Recent Trends in Research on Intestinal Flora, Microecology and Therapy 14, 267, 1984 (Intestinal Flora Associated Endotoxin), Microecology Therapy 16, 271-272, 1986 (Bifidobacterium bifidum administration in Humans: a Controlled Clinical Study in Liver Cirrhosis), etc.
In Italian Patent No. 1,022,625 food and pharmaceutical compositions which stimulates the production of gamma-interferon and contain lactobacilli Streptococcus thermophilus and Lactobacillus bulgaricus are described.
In U.S. Pat. No. 4,806,368, Reddy envisaged the possibility of preparing dietary fiber based tablets with Lactobacillus acidophilus and/or Bifidobacterium bifidus, Leuconostoc citrovorum and Propionibacterium shermanii. To enhance the viability of L. acidophilus in the tablets, a combination of aminoacids, vitamins, calcium, magnesium salts, lactose and dietary fiber were included. The optimal concentration of lactobacilli in each 750 mg tablet was not higher than 1×107. High concentrations were avoided.
Fernandes et al. in their comprehensive review “Therapeutic role of dietary lactobacilli and lactobacillic fermented diary products,” published in FEMS Microbiology Reviews 46:343-356, 1987, indicate moreover the beneficial effects of lactobacilli, especially of L. acidophilus.
Takano et al., U.S. Pat. No. 4,913,913, describes a method for preparing a bifidobacteria-containing fermented milk, in which Lactobacilius casei and Bifidobacterium longum are cultivated in admixture or are mixed after being separately cultivated, and thus a bifidobacteria-containing lactic acid bacteria-fermented milk with an elevated survival rate of Bifidobacterium longum is obtained.
No suggestion is found in the literature to prepare a composition which combines several different lactic bacteria. In addition, there is no indication in the prior art to suggest administering to humans a concentration of lactobacilli exceeding 109 per gram.
It has now been found that a composition comprising at least two lactic acid bacteria strains allows improved therapeutical results to be achieved of a kind never previously attained by prior art compositions, provided that the concentration of each of two lactic bacteria strains exceeds 1011 viable lactic bacteria/gram of composition.
It is therefore an object of the present invention to provide an appropriate dietary and pharmaceutical composition comprising lyophilized lactic bacteria at high concentration per gram of product (>1011 bacteria/gram), qualitatively and quantitatively coordinated so as to be used for treatment or for prevention of certain gastrointestinal disorders, or for treatment or prevention of hypocholesterolemia or to potentiate the host's immune system. The composition of the present invention can be used in combination with any of a variety of compatible drugs.
The present composition can be used to antagonize the onset of diarrhea, constipation, hypercholesteremia, endotoxin absorption or production of endogenous toxic substances.
The compositions of the present invention comprise as essential active ingredients: (a) from 10 to 95% by weight of total composition of lyophilized lactic bacterium Streptococcus thermophilus, and (b) from 90 to 5% by weight of total composition of at least one further lyophilized lactic bacterium selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei. An excipient in an amount of from 1 to 10% by weight of total components can be added, said amounts being all based on the total weight of the composition. The composition can be used in combination with a compatible pharmaceutical in an amount of from 1 to 20% by weight based on the total weight of the composition. It is essential that the viable bacteria concentration be at least 1×1011 for (a) and 1×1011 for (b) per gram of the composition. Preferably, the viable bacteria concentration of both (a) and (b) should be used between 1×1011 and 1×1013 per gram of the composition.
The compositions of the invention can be prepared with methods well-known to those skilled in dairy technology, enabling the presence of viable bacteria at concentrations ranging between 1×1011 and 1×1013 bacteria per gram of the composition.
According to a preferred embodiment, the composition should also contain from 85 to 5% by weight of one or more lyophilized lactic bacteria selected from bifidobacteria (preferably a mixture of lyophilized Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium infantis, ratio of 1:1:1 by weight) at a concentration ranging between 1×109 and 1×1012 viable bacteria per gram of the composition, lyophilized Lactobacillus acidophilus at a concentration of from 1×109 to 1×1012 viable bacteria per gram of the composition, lyophilized lactobacillus delbruekii sub-species bulgaricus at a concentration of from 1×109 to 1×1012 viable bacteria per gram of the composition, and lyophilized Streptococcus faecium at a concentration of from 1×109 to 1×1012 bacteria per gram of the composition, optionally with 1 to 10% of an excipient and 1 to 20% of a compatible pharmaceutical.
A particularly preferred composition according to the present invention contains: a) 31% by weight of lyophilized Streptococcus thermophilus, 7×1011; b) 7% by weight of lyophilized Lactobacillus casei, 1×1011; c) 8% by weight of lyophilized Lactobacillus plantarum, 1×1011; d) 7% by weight of lyophilized Lactobacillus acidophilus, 2×1010; e) 8% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus, 3×109; f) 27% by weight of lyophilized bifidobacteria, 38×1010; and g) 12% by weight of an excipient, wherein all the amounts are based on the total weight of the composition and Bifidobacterium Bifidum, Bifidobacterium longum and Bifidobacterium infantis.
As mentioned above, as further optional components the compositions of the invention may contain usual excipients as are conventionally used for preparing pharmaceutical compositions in which normally the ratio of the active ingredient to the excipient will range between 1:10 and 99:90.
The compositions of the invention can be made in conventional pharmaceutical forms, such as for example tablets, coated tablets, capsules, packets, solutions, sachets, suspensions, emulsions, suppositories, pellets, syrups, vaginal suppositories, and are prepared in the usual m manner by mixing active ingredients in the mentioned amounts, eventually adding excipients and/or carriers, adjuvants and/or dispersing agents. Water may be used as the diluent. Organic solvents can be used in the form of adjuvants. Adjuvants can be for example, non-toxic organic solvents such as paraffines, vegetable oils (peanut oil or sesame oil), glycerine, glycols (propylene glycol, polyethylene glycol), solid carriers such as for example natural mineral flours (kaolin, talc), synthetic mineral flours (silicates for example), sugar (cane sugar for example), emulsifiers (alkylsulfonates or arylsulfonates and the like), dispersants (lignin, methylcellulose, starch and polyvinylpyrrolidone, for example) and lubricants (magnesium stearate, talc, stearic acid, sodium laurylsolfonate, for example). Preferred excipients for the composition of the invention are maltodextrin, microcrystalline cellulose, maize starch, levulose, lactose and dextrose.
The administration takes place in the usual manner, preferably by oral route. In this case pharmaceutical forms adapted to this end can obtain, in addition to usual excipients, also additives such as sodium citrate, calcium carbonate, calcium dihydrogen phosphate, together with several additional substances such as starch, gelatin and the like. In case of liquid compositions compatible colouring agents of flavoring substances may be added.
As an optional component, the compositions may contain such compatible pharmaceuticals as anticholinergies, antihistamines, analgesics, adrenergics, antiinflammatories, antiseptics, hepatoprotective agents, or antilipemic drugs, in amounts of from 1 to 20% by weight, based on the total weight of the composition. As mentioned above, for preparing the compositions, the individual microorganisms in the dehydrated form are mixed in appropriate proportions and the mixture is then admixed with the excipients or optionally with other pharmaceuticals.
The following studies were carried out using a composition of lyophilized viable Streptococcus thermophilus and Lactobacillus plantarum, at concentrations respectively of 6×1011 and 4×1011 per gram of the composition.
The formulation of the preparation was in form of sachets, each containing 3 g of the composition. All the following studies were carried out in human health volunteers and in patients enrolled after informed consent according to the Helsinki declaration. Medical and laboratory controls were done by physicians aware of the good usual clinical practice (GPC) as stated by the European Economic Community (EEC). Statistical analysis was carried out by a statistician, not directly involved in the study. T0, T1, T2, and T3 refer respectively to pre-treatment, after one, two and three weeks of treatment.
In 33 patients affected by chronic hepatitis following C virus infection (anti-HCV+) the administration of one sachet per day (3 g of the composition containing 60% by weight of Streptococcus thermophilus and 40% by weight of Lactobacillus plantarum) induced a reduction of the aspartate aminostransferase (AST) from 52±32 IU at TO to 45±27 IOU at T2, of the alanine aminotransferase (ALT) from 68±39 IU at TO to 58±31 IU at T2 and of gamma-glutamyltranspeptidase (gGT) from 52±49 IU at TO to 40±25 IU at T2. In the above patients the following symptoms improved during and/or the treatment: anorexia, itching, nausea, diarrhea, constipation and insomnia. No undesired reactions or side-effects were noted. In 21 of the above patients, AST, ALT, and/or gGT resulted normalized at T3. As control group, 26 patients were treated with 15 capsules per day of Infloran Berna (trade mark), a marketed preparation of Bifidobacerium bifidum (1×109 bacterial per capsule) and Lactobacillus acidophilus (1×109 bacteria per capsule). The usual recommended daily dose of Infloran is 3 capsules per day; therefore the experiments were carried out administering a five fold increased dosage of Infloran. Apart from the poor compliance on the treated patients, no subject evidenced any significant variation in the AST, ALT and gGT levels at T3 (AST from 54±30 in AT to TO 55±31 IU; ALT from 65±34 IU at TO to 64±31 IU at T2 and gGT from 51±37 IU at TO to 55±41 IU at T2. The difference among the two groups was always statistically significant with p values <0.05.
In 24 subjects with serum cholesterol levels at TO of 268±126 mg/dl two sachets (6 gr per day of the composition comprising 68% by weight of Streptococcus thermophilus, 28% by weight of Lactobacillus casei and 4% by weight of maltodextrin) were administered, and at T3 the levels were reduced to 219±175 mg/dl (p<0.5). In the control group treated with 15 capsules of Infloran per day, the serum cholesterol levels did not change (from 254±156 mg/dl at TO to 250±168 mg/dl at T3)_.
Fifteen patients with irritable bowel syndrome were treated for 2 weeks with a sachet (3 g of the composition of Example 1) per day. Before and after the treatment colonscopy was performed and multiple endoscopic biopsies, at least 2 samples in each site, were taken in the descending and sigmoid colon. On biopsy specimens histological studies have shown a reduced number of infiltrating inflammatory cells. In the faeces of the same patients the measurement of tumor necrosis factor alpha has shown that the levels of this cytokine are reduced following the treatment with the preparation, from 45±12 pg/ml to faecal supernatant to 12±5 pg/ml (p<0.01).
In 18 healthy volunteers, the following parameters were evaluated before, during and at the end of the administration of one sachet (3 g) per day. In this study, the composition per gram was:
-
- 31% by weight of lyophilized Streptococcus thermophilus, 7×1011
- 7% by weight of lyophilized Lactobacillus casei, 1×1011
- 8% by weight of lyophilized Lactobacillus plantarum, 1×1011
- 7% by weight of lyophilized Lactobacillus acidophilus, 2×1010
- 8% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus, 3×109,
- 27% by weight of a mixture of lyophilized Bifidobacteria, 38×1010,
- 12% by weight of microcrystalline cellulose.
T0 | T1 | T2 | T3 | ||
CHOLESTEROL (mg/dl) |
average | 190.6 | 179.0 | 174.4 | 184.2 | |
Maximum | 285.3 | 264.8 | 247.5 | 267.4 | |
Minimum | 108.3 | 118.1 | 108.6 | 113.6 | |
SD | 59.9 | 44.7 | 44.0 | 54.3 |
AST (IU/ml) |
average | 29.8 | 25.8 | 26.0 | 23.3 | |
Maximum | 97.3 | 88.1 | 81.5 | 59.1 | |
Minimum | 13.2 | 6.8 | 10.8 | 10.8 | |
SD | 23.1 | 22.0 | 19.1 | 13.7 |
ALT (IU/ml) |
average | 31.9 | 31.2 | 26.6 | 24.5 | |
Maximum | 131.6 | 132.6 | 99.1 | 91.0 | |
Minimum | 10.1 | 7.1 | 7.5 | 6.7 | |
SD | 34.5 | 35.4 | 26.3 | 24.1 |
gG T (IU/ml) |
average | 41.2 | 40.3 | 37.5 | 38.5 | |
Maximum | 127.0 | 137.8 | 129.1 | 125.6 | |
Minimum | 12.3 | 12.5 | 9.2 | 9.7 | |
SD | 34.3 | 37.1 | 35.4 | 34.3 |
NK Activity (12.5:1) |
average | 44.0 | 67.5 | 49.9 | 41.0 | |
Maximum | 62.0 | 97.0 | 62.0 | 56.0 | |
Minimum | 24.0 | 47.0 | 25.0 | 14.0 | |
SD | 12.2 | 16.9 | 11.4 | 14.1 |
NK Activity (25:1) |
average | 56.4 | 80.5 | 54.6 | 48.1 | |
Maximum | 66.0 | 100.0 | 69.0 | 63.0 | |
Minimum | 42.0 | 51.0 | 37.0 | 23.0 | |
SD | 9.8 | 13.3 | 9.5 | 12.0 |
NK Activity (50:1) |
average | 60.8 | 87.8 | 59.1 | 51.8 | |
Maximum | 74.0 | 100.0 | 65.0 | 63.0 | |
Minimum | 48.0 | 69.0 | 42.0 | 30.0 | |
SD | 7.5 | 10.5 | 6.9 | 11.1 |
CD4 TO CD8 CELL RATIO |
average | 1.45 | 1.75 | 1.64 | 1.27 | ||
Maximum | 2.71 | 4.10 | 4.32 | 2.76 | ||
Minimum | 0.96 | 1.05 | 0.97 | 0.58 | ||
SD | 0.57 | 0.87 | 0.95 | 0.60 | ||
In the above subjects, fecal examination showed a mean increase of lactobacillus species from <1×106 colony forming units (CFU) per gram of fecal material to 64×106 CFU and of bifidobacteria species from <1×106 CFU to 68×106.
Strains used in the following formulation, given by way of example only, are as follows:
-
- thermophile Streptococci (ATCC 19987) consists of a mixture of two strains from a yogurt culture and a starter used for preparation of cheeses;
- Lactobacillus delbrueckii sub-species bulgaricus (ATCC 7994) is represented by a strain isolated from a yogurt culture;
- Lactobacillus acidophilus (ATCC 43121) is present in a mixture consisting of two strains of human origin isolated from a special yogurt;
- Bifidobacteria (Bifidobacterium infantis (ATCC 15697). Bifidobacterium longum (ATCC 15707), Bifidobacterium bifidum (ATCC 35914)) come from the intestinal flora of newborn babies;
- Lactobacillus casei (ATCC 334) has been isolated from a culture employed in the production of cheeses, and
- Lactobacillus plantarum (ATCC 8289) has been isolated from vegetables in progress of fermentation.
In order to obviate problems due to possible phage attacks, these strains can obviously be replaced by other cultures having the same features and origins, but provided with a different phage sensitiveness.
The individual strains maintained in a lyophilized and frozen form have been grown in synthetic media specific for each species. The fundamental component of the culture medium is permeate obtained by ultrafiltration of serum or milk, to which minimal amounts of biological activators are added depending on the species. After sterilization, the culture medium is inoculated with a strain per species or 1 to 3 strains belonging to the same genotype. Cultures have been incubated upon determination of optimal parameters for each strain: temperature, time, pH values and stirring.
Industrial cultures have been concentrated by centrifugation and lyophilization has been then carried out according to standard methodologies.
After lyophilization the cell mass has been pulverized under sterile conditions. The individual cultures submitted to chemical and microbiological tests have been maintained at 5° C. in hermetic vessels.
1) Streptococcus thermophilus (ATCC 19987)
Mother
The mother has been prepared by inoculating the strain in a medium consisting of 5% of permeate +1% of yeast extract and incubated at 44° C. over 3 hours.
Medium |
Permeate | 5% | |
Yeast extract | 1% |
Fermentation parameters |
Fermenter: | 72% 1 Applikon | |
Percent of inoculation: | 1% | |
Incubation temperature | 44° C. | |
Stirring speed | 160 rpm | |
Neutralization set point | pH = 6.00 | |
Neutralizing substance type: | ammonium hydrate | |
(sol to 10%) | ||
Fermentation time: | 3 h 30 m | |
Final cooling: | 24° C. |
Concentration parameters |
Centrifuge type: | Westfalia SA1 | |
Centrifugation temperature: | 24° C. | |
flow rate: | 24 l/h |
(The concentrate was then centrifuged again using a | |
laboratory centrifuge at 6000 rpm over 20 minutes). |
Lyophilization |
Lyophilizer | Edwards MINI - | ||
FAST 3400 | |||
Lyophilization protector: | a solution of | ||
lactose | |||
Results: the number of microorganisms during the different steps of the process are reproduced in the following Table:
Steps | U.F.C./g | ||
End of fermentation | 2.4E9 | ||
Concentrate | 1.6E11 | ||
Lyophilized | 7.4E11 | ||
U.F.C. = Colony-forming units | |||
E9 = one thousand millions | |||
E11 = one hundred thousand millions |
No particular problems have been found in the preparation of this microorganisms. Therefore the cell loss during the different steps of the process could be greatly limited and a high bacterial charge could be achieved in the lyophilized product.
2) Lactobacillus plantarum (ATCC 8289)
Mother
Prepared in MRS culture medium and incubated at 33° C. over 5 hours.
Medium |
Permeate | 5% | |
Yeast extract | 1% | |
Glucose | 2.5% |
Fermentation parameters |
Fermenter: | Applikon | ||
Percent of inoculation: | 1% | ||
Incubation temperature | 33° C. | ||
Stirring speed | 110 rpm | ||
Neutralization set point | pH = 6.00 | ||
Neutralizing substance type: | ammonium hydrate | ||
(sol to 10%) | |||
Fermentation time: | 15 h | ||
Cell inactivation after fermentation by pasteurization at 80° C. over 15 minutes.
Concentration parameters |
Centrifuge type: | Westfalia SA1 | |
Centrifugation temperature: | 60° C. | |
Flow rate: | 40 l/h |
Lyophilization |
Lyophilizer | Edwards MINI - | ||
FAST 3400 | |||
Lyophilization protector: | a solution of | ||
lactose | |||
The number of microorganisms during the different process steps is reproduced in the following Table:
Steps | U.F.C.G | Count/g in | ||
Thoma | ||||
End of fermentation | 9.2E8 | — | ||
Lyophilized | — | 1.0E11 | ||
U.F.C. = colony-forming units | ||||
E8 = one hundred millions | ||||
E11 = one hundred thousand millions. |
3) Lactobacillus casei (ATCC 334)
Mother
Prepared in MRS culture medium and incubated at 37° C. over 8 hours and 30 minutes
Medium |
Permeate | 5% | |
Yeast extract | 1% | |
Glucose | 1% |
Fermentation parameters |
Fermenter: | Applikon | |
Inoculation percent: | 1% | |
Incubation temperature | 37° C. | |
Stirring speed | 110 rpm | |
Neutralization set point | pH = 5.40 | |
Neutralizing substance type: | ammonium hydrate | |
(sol to 10%) | ||
Fermentation time: | 15 h |
Concentration parameters |
Centrifuge type: | Westfalia SA1 | |
Centrifugation temperature: | 60° C. | |
Flow rate: | 46 l/h |
Lyophilization |
Lyophilizer | Edwards MINI - | ||
FAST 3400 | |||
Lyophilization protector: | a lactose solution | ||
Results: the number of microorganisms during the different process steps is reproduced in the following Table:
Steps | U.F.C.G | Count/g in | ||
Thoma | ||||
End of fermentation | 1.0E9 | — | ||
Lyophilized | — | 1.0E11 | ||
U.F.C. = Colony-forming units | ||||
E8 = one hundred millions | ||||
E11 = one hundred thousand millions. |
4) Mixture of bifidobacteria (Bifodobacterium infantis (ATCC 15697)—Bifidobacterium longum (ATCC 15707)—Bifodobacterium bifidum (ATCC 35914), ratio 1:1:1 by weight)
Mother
The mother has been prepared by inoculating the strains in a medium consisting of 10% of powdered skimmed milk +0.5% of glucose +1% of yeast extract and incubated at 38° C. over 15 hours.
Medium |
Permeate | 4% | |
Yeast extract | 1% | |
Bacto Soytone | 0.25% | |
Glucose | 0.5% |
Fermentation parameters |
Fermenter: | Applikon | |
Inoculation percent: | 2% | |
Incubation temperature | 38° C. | |
Stirring speed | 110 rpm | |
Neutralization set point | pH = 6.00 | |
Neutralizing substance type: | ammonium hydrate | |
(sol to 10%) | ||
Fermentation time: | 15 h | |
Cooling at the end of fermentation: | 24° C. |
Concentration parameters |
Centrifuge type: | Westfalia SA1 | |
Centrifugation temperature: | 24° C. | |
Flow rate: | 42 l/h |
(The obtained concentrate has been then centrifuged again | |
with a laboratory centrifuge at 6000 rpm over 20 minutes) |
Lyophilization |
Lyophilizer | Edwards MINI - | ||
FAST 3400 | |||
Lyophilization protector: a solution of powdered skimmed milk+yeast extract+lactose+sodium maleate has been prepared.
Results: the number of microorganisms during the different process steps is reproduced in the following Table:
Steps | U.F.C.G | ||
End of fermentation | 1.7E9 | ||
Concentrate | 7.0E10 | ||
Lyophilized | 3.8E11 | ||
U.F.C. = Colony-forming units | |||
E9 = one thousand millions | |||
E10 = ten thousand millions | |||
E11 = one hundred thousand millions. |
In this case too, in which bacteria are considered of “hard” growing, no particular problems have been found during the different preparation steps and the number of microorganisms is high both in the fermentation and on the lyophilized.
5) Lactobacillus acidophilus (ATCC 43121)
Mother
Prepared in a medium consisting of 5% of permeate+1% of yeast extract+1% of glucose+1% of Tween (Registered Trademark) 80 and incubated at 37° C. over 15 hours.
Medium |
Permeate | 5% | |
Yeast extract | 1% | |
Glucose | 1% | |
Tween (Registered Trademark) 80 | 0.1% |
Fermentation parameters |
Fermenter: | Applikon | |
Inoculation percent: | 1% | |
Incubation temperature | 37° C. | |
Stirring speed | 110 rpm | |
Neutralization set point | pH = 6.00 | |
Neutralizing substance type: | ammonium hydrate | |
(sol to 10%) | ||
Fermentation time: | 15 h | |
Cooling at the end of fermentation: | 24° C. |
Concentration parameters |
Centrifuge type: | Westfalia SA1 | |
Centrifugation temperature: | 24° C. | |
Flow rate: | 42 l/h |
(The obtained concentrate has been then centrifuged again | |
with a laboratory centrifuge at 6000 rpm over 20 minutes) |
Lyophilization |
Lyophilizer | Edwards MINI - | ||
FAST 3400 | |||
Lyophilization protector: a solution of lactose and anhydrous mixture consisting of powdered skimmed milk+yeast extract+lactose+sodium maleate+Tween (Registered Trademark) 80. Results: the number of microorganisms during the different process steps is reproduced in the following Table:
Steps | U.F.C./g | ||
End of fermentation | 2.9E8 | ||
Concentrate | 2.3E10 | ||
Lyophilized | 2.0E10 | ||
U.F.C. = Colony-forming units | |||
E8 = one hundred millions | |||
E10 = ten thousand millions |
6) Lactobacillus delbrueckii sub-species bulgaricus (ATCC 7994)
Mother
Prepared in a medium consisting of 5% of permeate+1% of yeast extract+1% of beef extract+1% of glucose+0.1% of Tween (Registered Trademark) 80 and incubated at 44° C. over 4 hours and 30 minutes.
Medium |
Permeate | 5% | |
Yeast extract | 1% | |
Beef extract | 1% | |
Glucose | 1% | |
Tween (Registered Trademark) 80 | 0.1% |
Fermentation parameters |
Fermenter: | Applikon | |
Inoculation percent: | 1% | |
Incubation temperature | 44° C. | |
Stirring speed | 110 rpm | |
Neutralization set point | pH = 5.60 | |
Neutralization substance type: | ammonium hydrate | |
(sol to 10%) | ||
Fermentation time: | 7 h | |
Cooling at the end of fermentation: | 24° C. |
Concentration parameters |
Installation: pilot unit for Hydro Air Research | |
microfiltration with two serial ceramic diaphragms each | |
having a 0.2 m2 filtrating surface. |
Microfiltration temperature | 30° C. | |
Operating conditions | recirculation | |
flow rate 4000 l/h | ||
input pressure | ||
2.7 bar | ||
output pressure | ||
1.2 bar | ||
average flow of | ||
the permeate 30 l/h × m2 |
(The obtained concentration has been then centrifuged again | |
with a laboratory centrifuge at 6000 rpm over 20 minutes). |
Lyophilization |
Lyophilizer | Edwards MINI - | ||
FAST 3400 | |||
Lyophilization protector: a solution of lactose and anhydrous mixture consisting of powdered skimmed milk+yeast extract+lactose+sodium glutamate+Tween (Registered Trademark) 80. Results: the number of micoorganisms during the different process steps is reproduced in the following Table:
Steps | U.F.C./g | ||
End of fermentation | 2.9E9 | ||
Concentrate | 2.4E10 | ||
Lyophilized | 3.5E9 | ||
U.F.C. = Colony-forming units | |||
E9 = one thousand millions | |||
E10 = ten thousand millions |
Claims (33)
1. A pharmaceutical composition comprising:
a) from 10% to 95% by weight of total composition of lyophilized Streptococcus thermophilus, and
b) from 5% to 90% by weight of total composition of at least one lyophilized bacterium selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei, and
c) from 0% to 10% by weight of total composition a pharmaceutically acceptable excipient,
wherein said Streptococcus thermophilus and the bacterium b) are present in a concentration of 1×1011-1×1013 total bacteria per gram of the composition.
2. The pharmaceutical composition of claim 1 which further contains an excipient in an amount of 1 to 10% by weight based on total composition.
3. The pharmaceutical composition of claim 2 , wherein said excipient is selected from the group consisting of maltodextrin, microcrystalline cellulose, maize starch, levulose, lactose and dextrose.
4. The pharmaceutical composition of claim 1 which further contains from 85% to 5% by weight of one or more lyophilized bacteria selected from the group consisting of bifidobacteria, Lactobacillus acidophilus, Lactobacillus delbrueckii sub-species bulgaricus and Streptococcus faecium, wherein the concentration of this bacterium is from 1×109 to 1×1012 bacteria per gram of the composition.
5. The pharmaceutical composition of claim 4 , wherein said bifidobacteria is a mixture of Bifidobacterium longum, Bifidobacterium bifidum and Bifidobacterium infantis is approximately in equal weight distribution.
6. The pharmaceutical composition of claim 1 , which further comprises from 1 to 20% by weight of total composition of a drug which is compatible with the bacteria in said composition.
7. The pharmaceutical composition of claim 6 , wherein said drug is selected from the group consisting of anticholinergics, antihistamines, analgesics, adrenergics, antiinflammatories, antiseptics, hepatoprotective agents and antilipemics.
8. The pharmaceutical composition according to claim 1 , which contains 1 to 10% by weight of total composition of said pharmaceutically acceptable excipient.
9. A pharmaceutical composition comprising:
(a) from 30-35% by weight of lyophilized Streptococcus thermophilus;
(b) from 7-10% by weight of lyophilized Lactobacillus casei;
(c) from 8-10% by weight of lyophilized Lactobacillus plantarum;
(d) from 7-10% by weight of lyophilized Lactobacillus acidophilus;
(e) from 8-10% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus;
(f) from 27-30% by weight of a mixture of lyophilized bifidobacteria; and
(g) from 8-10% by weight of a pharmaceutically acceptable excipient,
wherein all amounts are based on the total weight of the composition and said bifidobacteria is a mixture of Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum;
wherein said excipient is selected from the group consisting of maltodextrin, levulose, microcrystalline cellulose, maize starch, lactose, and dextrose; and
wherein said Streptococcus thermophilus, said Lactobacillus casei, and said Lactobacillus plantarum are present in said pharmaceutical composition in a total concentration of 1×1011 to 1×1013 bacteria per gram.
10. The pharmaceutical composition of claim 9 , wherein said bifidiobacteria is a mixture 1:1:1 by weight.
11. A method for treating hypercholesteremia, comprising administering to a patient in need thereof an effective amount of a composition, said composition comprising:
(a) from 10 to 95% by weight of total composition of lyophilized Streptococcus thermophilus;
(b) from 5 to 90% by weight of total composition of at least one lyophilized bacteria selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei; and
(c) from 0 to 10% by weight of total composition of a pharmaceutically acceptable excipient;
wherein said Streptococcus thermophilus, Lactobacillus plantarum, and Lactobacillus casei are present in such amounts that the total bacteria concentration in said composition is 1×1011 to 1×1013 total bacteria per gram of composition.
12. The method of claim 11 , wherein said composition comprises 1 to 10% by weight of said excipient.
13. The method of claim 12 , wherein said excipient is selected from the group consisting of maltodextrin, microcrystalline cellulose, maize starch, levulose, lactose, and dextrose.
14. The method of claim 11 , wherein said composition further comprises from 85% to 5% by weight of one or more lyophilized bacteria selected from the group consisting of bifidobacteria, Lactobacillus acidophilus, Lactobacillus delbrueckii sub-species bulgaricus and Streptococcus faecium, in a concentration of from 1×109 to 1×1012 bacteria per gram of said composition.
15. The method of claim 14 , wherein said bifidobacteria is a mixture of Bifidobacterium longum, Bifidobacterium bifidum and Bifidobacterium infantis in approximately an equal weight distribution.
16. The method of claim 11 , wherein said composition comprises:
(a) from 30-35% by weight of lyophilized Streptococcus thermophilus;
(b) from 7-10% by weight of lyophilized Lactobacillus casei;
(c) from 8-10% by weight of lyophilized Lactobacillus plantarum;
(d) from 7-10% by weight of lyophilized Lactobacillus acidophilus;
(e) from 8-10% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus;
(f) from 27-30% by weight of lyophilized bifidobacteria; and
(g) from 8-10% by weight of an excipient, wherein all amounts are based on the total weight of said composition and said bifidobacteria is a mixture 1:1:1 by weight of Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum, and said excipient is selected from the group consisting of maltodextrin, levulose, microcrystalline cellulose, maize starch, lactose, and dextrose.
17. The method of claim 11 , wherein said administering is oral administration.
18. A method for treating a gastrointestinal disorder, comprising administering to a patient in need thereof an effective amount of a composition, said composition comprising:
(a) from 10 to 95% by weight of total composition of lyophilized Streptococcus thermophilus;
(b) from 5 to 90% by weight of total composition of at least one lyophilized bacteria selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei; and
(c) from 0 to 10% by weight of total composition of a pharmaceutically acceptable excipient;
wherein aid Streptococcus thermophilus, Lactobacillus plantarum, and Lactobacillus casei are present in such amounts that the total bacteria concentration in said composition is 1×1011 to 1×1013 total bacteria per gram of composition.
19. The method of claim 18 , wherein said composition comprises 1 to 10% by weight of said excipient.
20. The method of claim 19 , wherein said excipient is selected from the group consisting of maltodextrin, microcrystalline cellulose, maize starch, levulose, lactose, and dextrose.
21. The method of claim 18 , wherein said composition further comprises from 85% to 5% by weight of one or more lyophilized bacteria selected from the group consisting of bifidobacteria, Lactobacillus acidophilus, Lactobacillus delbrueckii sub-species bulgaricus, and Streptococcus faecium, in a concentration of from 1×109 to 1×1012 bacteria per gram of said composition.
22. The method of claim 21 , wherein said bifidobacteria is a mixture of Bifidobacterium longum, Bifidobacterium bifidum, and Bifidobacterium infantis in approximately an equal weight distribution.
23. The method of claim 18 , wherein said composition comprises:
(a) from 30-35% by weight of lyophilized Streptococcus thermophilus;
(b) from 7-10% by weight of lyophilized Lactobacillus casei;
(c) from 8-10% by weight of lyophilized Lactobacillus plantarum;
(d) from 7-10% by weight of lyophilized Lactobacillus acidophilus;
(e) from 8-10% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus;
(f) from 27-30% by weight of lyophilized bifidobacteria; and
(g) from 8-10% by weight of an excipient, wherein all amounts are based on the total weight of said composition and said bifidobacteria is a mixture 1:1:1 by weight of Bifidobacterium longum, Bifidobacterium infantis and Bifidobacterium bifidum, and said excipient is selected from the group consisting of maltodextrin, levulose, microcrystalline cellulose, maize starch, lactose, and dextrose.
24. The method of claim 18 , wherein said administering is oral administration.
25. The method of claim 18 , wherein said gastrointestinal disorder is diarrhea.
26. The method of claim 18 , wherein said gastrointestinal disorder is irritable bowel syndrome.
27. A method for modulating a host's immune response, comprising administering to a patient in need thereof an effective amount of a composition, said composition comprising:
(a) from 10 to 95% by weight of total composition of lyophilized Streptococcus thermophilus;
(b) from 5 to 90% by weight of total composition of at least one lyophilized bacteria selected from the group consisting of Lactobacillus plantarum and Lactobacillus casei; and
(c) from 0 to 10% by weight of total composition of a pharmaceutically acceptable excipient;
wherein said Streptococcus thermophilus, Lactobacillus plantarum, and Lactobacillus casei are present in such amounts that the total bacteria concentration in said composition is 1×1011 to 1×1013 total bacteria per gram of composition.
28. The method of claim 27 , wherein said composition comprises 1 to 10% by weight of said excipient.
29. The method of claim 28 , wherein said excipient is selected from the group consisting of maltodextrin, microcrystalline cellulose, maize starch, levulose, lactose, and dextrose.
30. The method of claim 27 , wherein said composition further comprises from 85% to 5% by weight of one or more lyophilized bacteria selected from the group consisting of bifidobacteria, Lactobacillus acidophilus, Lactobacillus delbrueckii sub-species bulgaricus, and Streptococcus faecium, in a concentration of from 1×109 to 1×1012 bacteria per gram of said composition.
31. The method of claim 30 , wherein said bifidobacteria is a mixture of Bifidobacterium longum, Bifidobacterium bifidum and Bifidobacterium infantis in approximately an equal weight distribution.
32. The method of claim 27 , wherein said composition comprises:
(a) from 30-35% by weight of lyophilized Streptococcus thermophilus;
(b) from 7-10% by weight of lyophilized Lactobacillus casei;
(c) from 8-10% by weight of lyophilized Lactobacillus plantarum;
(d) from 7-10% by weight of lyophilized Lactobacillus acidophilus;
(e) from 8-10% by weight of lyophilized Lactobacillus delbrueckii sub-species bulgaricus;
(f) from 27-30% by weight of lyophilized bifidobacteria; and
(g) from 8-10% by weight of an excipient, wherein all amounts are based on the total weight of said composition and said bifidobacteria is a mixture 1:1:1 by weight of Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum, and said excipient is selected from the group consisting of maltodextrin, levulose, microcrystalline cellulose, maize starch, lactose, and dextrose.
33. The method of claim 27 , wherein said administering is oral administration.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/375,704 USRE40023E1 (en) | 1992-02-10 | 2006-03-15 | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI920256A IT1254210B (en) | 1992-02-10 | 1992-02-10 | DIETARY AND / OR PHARMACEUTICAL COMPOSITIONS BASED ON LYOPHILIZED LACTIC BACTERIA, THEIR PREPARATION AND USE |
US98383992A | 1992-12-01 | 1992-12-01 | |
US11775193A | 1993-09-08 | 1993-09-08 | |
US08/448,787 US5716615A (en) | 1992-02-10 | 1995-05-24 | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
US11/375,704 USRE40023E1 (en) | 1992-02-10 | 2006-03-15 | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/448,787 Reissue US5716615A (en) | 1992-02-10 | 1995-05-24 | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE40023E1 true USRE40023E1 (en) | 2008-01-22 |
Family
ID=38950987
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/448,787 Ceased US5716615A (en) | 1992-02-10 | 1995-05-24 | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
US11/375,704 Expired - Lifetime USRE40023E1 (en) | 1992-02-10 | 2006-03-15 | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/448,787 Ceased US5716615A (en) | 1992-02-10 | 1995-05-24 | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use |
Country Status (1)
Country | Link |
---|---|
US (2) | US5716615A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41276E1 (en) * | 1996-03-11 | 2010-04-27 | Vsl Pharmaceuticals, Inc. | Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases associated with or caused by altered metabolism of bile acids |
US20110217368A1 (en) * | 2009-05-01 | 2011-09-08 | Satya Prakash | Bacterial compositions for prophylaxis and treatment of degenerative disease |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ369297A3 (en) * | 1995-05-23 | 1998-05-13 | Smithkline Beecham Plc | Process for preparing liquid aromatized pharmaceutical preparation |
US6899872B1 (en) * | 1995-11-27 | 2005-05-31 | Standa Lab Sa | Absorbable dietary composition for improving the biological balance of intestinal tract flora |
IT1288119B1 (en) | 1996-06-28 | 1998-09-10 | Renata Maria Anna Ve Cavaliere | DIETARY COMPOSITIONS TO BE USED IN FEEDING VIA ENTERICA |
US8828432B2 (en) * | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
IT1296148B1 (en) * | 1996-11-22 | 1999-06-09 | Renata Maria Anna Ve Cavaliere | USE OF LACTIC BACTERIA TO INCREASE THE LEVEL OF CERAMIDES OF THE SKIN AND MUCOSA, AND SUITABLE DERMATOLOGICAL AND COSMETIC COMPOSITIONS |
ES2283027T3 (en) * | 1996-11-29 | 2007-10-16 | Bio K + International Inc. | LACTIC FERMENT THAT INCLUDES A PARTICULAR CEPA OF LACTOBACILUS ACIDOFILUS AND USE OF THE SAME. |
EP0856259B1 (en) * | 1996-12-23 | 1998-08-12 | SITIA-YOMO S.p.A. | Composition for feed use comprising lyophilized live lactic bacteria |
US6098795A (en) * | 1997-10-14 | 2000-08-08 | Mollstam; Bo | Device for adding a component to a package |
SE510813C2 (en) * | 1997-12-08 | 1999-06-28 | Arla Ekonomisk Foerening | Bacterial strain of the species Lactobacillus Paracasei subsp. paracasei, its composition for use in food, and product containing the strain |
DE69941212D1 (en) * | 1998-03-23 | 2009-09-17 | Gen Mills Inc | PLASTERING COMPONENTS IN EDIBLE PRODUCTS |
US7201923B1 (en) * | 1998-03-23 | 2007-04-10 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
US6368591B2 (en) * | 1998-05-15 | 2002-04-09 | Shanghai Sine Pharmaceutical Corporation Ltd. | Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof |
US7029702B2 (en) * | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
FR2785809B1 (en) | 1998-11-18 | 2001-01-12 | Gervais Danone Sa | SELECTION AND USES OF STRAINS OF LACTIC BACTERIA MODULATING NON-SPECIFIC IMMUNITY |
IT1304170B1 (en) | 1998-12-15 | 2001-03-08 | Novartis Nutrition Ag | ORGANIC COMPOUNDS |
US20040161422A1 (en) * | 1999-04-30 | 2004-08-19 | Natarajan Ranganathan | Nutritional compositions comprising probiotics |
US20040105848A1 (en) * | 1999-04-30 | 2004-06-03 | Natarajan Ranganathan | Enteric dialysis compositions and methods |
US7998470B2 (en) * | 1999-04-30 | 2011-08-16 | Kibow Biotech, Inc. | Compositions and methods improving renal function |
IT1311495B1 (en) * | 1999-06-09 | 2002-03-13 | Mendes S U R L | COMPOSITION INCLUDING ALKALINE SPHYNOMYELINASE, USABLE AS A DIETARY PRODUCT, FOOD SUPPLEMENT OR MEDICATION. |
US8697051B2 (en) | 1999-06-09 | 2014-04-15 | Vsl Pharmaceuticals Inc. | Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
US20040166101A1 (en) * | 1999-09-22 | 2004-08-26 | Bojrab Gregory G. | Enchanced composition for treatment of gastrointestinal disorders and hyperlipidemia |
US6641808B1 (en) * | 1999-09-22 | 2003-11-04 | Lacpro Industries, Llc | Composition for treatment of obesity |
US6696057B1 (en) | 1999-09-22 | 2004-02-24 | Lacpro Industries, Inc. | Composition and method for treatment of gastrointestinal disorders and hyperlipidemia |
US6444203B2 (en) | 1999-12-20 | 2002-09-03 | Compagnie Gervais Danone | Administering bacteria to improve sleep |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
IL151345A0 (en) * | 2000-02-23 | 2003-04-10 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
MXPA02009342A (en) * | 2000-03-24 | 2003-09-22 | Nestle Sa | Use of lactic acid bacterium for the treatment of peritonitis. |
KR20020043078A (en) * | 2000-12-01 | 2002-06-08 | 한인규 | Oligosaccharide and Probiotics Complex |
WO2003013558A1 (en) * | 2001-07-30 | 2003-02-20 | Claudio De Simone | Treatment of radiation-induced diarrhea with probiotics |
US20030091971A1 (en) * | 2001-09-14 | 2003-05-15 | Invitrogen Corporation | Composition for stabilizing biological materials |
FR2831395B1 (en) * | 2001-10-25 | 2004-06-11 | Triballat Laiteries | PROCESS FOR THE PRODUCTION OF FERMENTED SOYBEAN PRODUCTS, FERMENTED PRODUCTS OBTAINED THEREBY AND CORRESPONDING FERMENTS |
ITRM20010763A1 (en) * | 2001-12-21 | 2003-06-21 | Simone Claudio De | NEW LACTIC BACTERIA STOCK AND EDIBLE COMPOSITIONS, DRUGS AND VETERINARY PRODUCTS THAT CONTAIN IT. |
ITMI20020399A1 (en) | 2002-02-28 | 2003-08-28 | Ct Sperimentale Del Latte S P | DIETARY AND / OR PHARMACEUTICAL COMPOSITIONS FOR HUMAN AND / OR ANIMAL USE BASED ON MICROBIAL PROBIOTIC PREPARATIONS |
US20050074442A1 (en) * | 2002-03-13 | 2005-04-07 | Natarajan Ranganathan | Compositions and methods for augmenting kidney function |
US9980988B2 (en) | 2002-03-13 | 2018-05-29 | Kibow Biotech, Inc. | Compositions and methods for augmenting kidney function |
US9655932B2 (en) | 2002-03-13 | 2017-05-23 | Kibow Biotech, Inc. | Composition and method for preventing or treating gout or hyperuricemia |
US11103542B2 (en) * | 2002-03-13 | 2021-08-31 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
DE10223856A1 (en) * | 2002-05-28 | 2003-12-18 | Nutrinova Gmbh | Anti-inflammatory and chemopreventive |
US7431986B2 (en) * | 2002-07-24 | 2008-10-07 | General Mills, Inc. | Encapsulation of sensitive components using pre-emulsification |
AU2003282494A1 (en) * | 2002-10-11 | 2004-05-04 | Wyeth | Nutritional formulations containing synbiotic substances |
ITMI20022343A1 (en) * | 2002-11-05 | 2004-05-06 | Biofarm Srl | FAST DISSOLUTION FILM IN WATER, CONTAINING COSMETIC, AROMATIC, PHARMACEUTICAL OR FOOD SYSTEMS. |
ATE354964T1 (en) * | 2003-05-22 | 2006-03-15 | Synbiotics Ab | PROBIOTIC COMPOSITION CONTAINING AT LEAST TWO STRAINS OF LACTIC ACID BACTERIA THAT ARE CAPABLE OF COLONIZING THE GASTROINTESTINAL TRACT AND, IN COMBINATION, HAVE THE PROPERTIES OF SURVIVE IN THE INTESTINAL, BINDING TO THE INTESTINAL, PROTECTING AGAINST INFECTION AND FERMENTING FIBER |
WO2005076824A2 (en) * | 2004-02-03 | 2005-08-25 | The Regents Of The University Of California | Methods of treating irritable bowel syndrome |
WO2006012536A2 (en) * | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
US7803413B2 (en) | 2005-10-31 | 2010-09-28 | General Mills Ip Holdings Ii, Llc. | Encapsulation of readily oxidizable components |
DE102005062731A1 (en) * | 2005-12-22 | 2007-06-28 | Organobalance Gmbh | New Lactobacillus strains and their use |
FR2895877B1 (en) * | 2006-01-06 | 2012-06-22 | Gervais Danone Sa | FERMENTED MILK POWDER OR YOGURT WITH HIGH DENSITY IN LACTIC FERMENTS |
US20070255598A1 (en) * | 2006-03-29 | 2007-11-01 | Mccarthy Nancy J | Compliance aid, kits comprising the compliance aid, and methods of use |
US20110165127A1 (en) * | 2006-06-09 | 2011-07-07 | Fabiola Masri | Dairy-derived probiotic compositions and uses thereof |
US8304226B2 (en) | 2006-08-22 | 2012-11-06 | Carl Miller | Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine |
US8007783B2 (en) * | 2006-08-22 | 2011-08-30 | Carl Miller | Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine |
WO2008036719A2 (en) * | 2006-09-19 | 2008-03-27 | Powlen Owen J | Animal feed supplements and uses thereof |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
US20110189148A1 (en) * | 2008-06-25 | 2011-08-04 | Ritter Pharmaceuticals, Inc. | Lactose compositions with decreased lactose content |
WO2010098822A1 (en) | 2009-02-24 | 2010-09-02 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
DK2228436T3 (en) | 2009-03-06 | 2016-04-11 | Dupont Nutrition Biosci Aps | The centrifugation and filtration methods for concentrating micro-organisms |
EP2437616A4 (en) * | 2009-06-05 | 2013-08-21 | Gen Mills Inc | Encapsulated omega-3 fatty acids for baked goods production |
WO2011044516A2 (en) * | 2009-10-09 | 2011-04-14 | Prothera, Inc. | Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
EP2533803B1 (en) | 2010-02-11 | 2016-01-20 | Technische Universität München | Lactocepins for use in the treatment of ip-10-mediated inflammatory diseases |
WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
EP2532354A1 (en) | 2011-06-08 | 2012-12-12 | OrganoBalance GmbH | Spray-dried lactobacillus strains/cells and the use of same against helicobacter pylori |
MX354047B (en) * | 2011-06-08 | 2018-02-09 | Novozymes As | SPRAY-DRIED <i>LACTOBACILLUS</i> STEMS / CELLS AND THE USE OF SAME AGAINST <i>HELICOBACTER PYLORI. |
EP2804613A4 (en) * | 2012-01-16 | 2015-12-09 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
US20140086849A1 (en) | 2012-09-21 | 2014-03-27 | Elizabeth McKenna | Naturally-Occurring CpG Oligonucleotide Compositions and Therapeutic Applications Thereof |
MX370537B (en) | 2013-02-07 | 2019-12-17 | Novozymes As | Composition comprising lactobacillus and a carrier. |
ITMI20131467A1 (en) | 2013-09-06 | 2015-03-07 | Sofar Spa | USE OF A COMPOSITION INCLUDING MICRO-ORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTIRRIC ACID, FOLIC ACID OR NIACINE ACID AND / OR TO REDUCE THE INTESTINAL PRODUCTION OF SUCCINIC ACID |
AU2015258769A1 (en) * | 2014-05-12 | 2016-12-01 | Medlab Ip Pty Ltd | Probiotic compositions and uses thereof for treatment of obesity-related disorders |
DK3209308T3 (en) | 2014-10-24 | 2022-10-03 | Evolve Biosystems Inc | ACTIVATED BIFIDOBACTERIA AND METHODS OF USING THEREOF |
CN116270760A (en) * | 2015-03-13 | 2023-06-23 | 英凡特健康有限公司 | Composition for metabolizing or sequestering free sugar monomers and use thereof |
MA45288A (en) | 2016-06-08 | 2019-04-17 | Sofar Spa | New medical use of probiotics |
IT201600127498A1 (en) | 2016-12-16 | 2018-06-16 | Sofar Spa | PROBIOTICS FOR USE IN DIVERTICULOSIS AND DIVERTICULAR DISEASE |
US11179426B2 (en) | 2016-12-29 | 2021-11-23 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
WO2020018482A1 (en) * | 2018-07-16 | 2020-01-23 | Stc.Unm | Treatment methods and compositions |
US20220160794A1 (en) * | 2019-05-14 | 2022-05-26 | Ormendes Sa | Use of bacillus amyloliquefaciens and/or bacillus subtilis for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions, compositions thus obtained, and related method |
US20230148645A1 (en) | 2020-04-09 | 2023-05-18 | Prabhakaran PANDURANGAN | Therapeutic composition |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4115199A (en) * | 1977-05-04 | 1978-09-19 | Chr. Hansen's Laboratory, Inc. | Preparation of culture concentrates for direct vat set cheese production |
US4205132A (en) * | 1978-07-17 | 1980-05-27 | Microlife Technics, Inc. | Lyophilization of bacteria |
US4226940A (en) * | 1979-06-21 | 1980-10-07 | Great Lakes Biochemical Co., Inc. | Non-frozen concentrated bacterial cultures |
US4588595A (en) * | 1982-11-09 | 1986-05-13 | Morinaga Milk Industry Co., Ltd. | Culture containing a viable cell mass of Bifidobacteria and lactic acid bacteria |
EP0228881A2 (en) * | 1985-12-20 | 1987-07-15 | Roger A. Draft | Tank overfill valve |
FR2609044A1 (en) * | 1986-12-30 | 1988-07-01 | Sperimentaledel Latte Centro | LACTIC FERMENTS IN SYMBIOTIC ASSOCIATION AND THEIR USE IN THE PREPARATION OF DAIRY, CHEESE AND FOOD PRODUCTS IN GENERAL |
EP0291578A1 (en) * | 1987-05-20 | 1988-11-23 | Kopalnia Soli "Wieliczka" | Table salt enriched in bioelements |
IT1200625B (en) * | 1985-05-30 | 1989-01-27 | Sitia Yomo Spa | Immuno-stimulating compsn. |
US4806368A (en) * | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
US4913913A (en) * | 1987-02-25 | 1990-04-03 | The Calpis Food Industry Co., Ltd. | Method of preparation of bifidobacteria-containing fermented milk |
US5108766A (en) * | 1990-10-22 | 1992-04-28 | Pierre Gelinas | Flavorants for enhancing the taste and flavor of bakery products and process of making |
US5128260A (en) * | 1989-01-12 | 1992-07-07 | Sanofi Bio Ingredients, Inc. | Process for preparing culture concentrates for direct vat set dairy products production |
US5143845A (en) * | 1986-09-03 | 1992-09-01 | Toa Pharmaceutical Co., Ltd. | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria |
US5219597A (en) * | 1991-02-20 | 1993-06-15 | Korea Food Research Institute | Method for producing highly concentrated, lactic-acid fermented product utilizing unground grainy rice and improving qualities thereof by the secondary, enzymatic treatment at fermentation |
US5474932A (en) * | 1991-07-25 | 1995-12-12 | Probi Ab | Intestine colonizing strains of lactobacilli |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0696538B2 (en) * | 1985-12-19 | 1994-11-30 | 株式会社アドバンス | Anti-carcinogen |
-
1995
- 1995-05-24 US US08/448,787 patent/US5716615A/en not_active Ceased
-
2006
- 2006-03-15 US US11/375,704 patent/USRE40023E1/en not_active Expired - Lifetime
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4115199A (en) * | 1977-05-04 | 1978-09-19 | Chr. Hansen's Laboratory, Inc. | Preparation of culture concentrates for direct vat set cheese production |
US4205132A (en) * | 1978-07-17 | 1980-05-27 | Microlife Technics, Inc. | Lyophilization of bacteria |
US4226940A (en) * | 1979-06-21 | 1980-10-07 | Great Lakes Biochemical Co., Inc. | Non-frozen concentrated bacterial cultures |
US4588595A (en) * | 1982-11-09 | 1986-05-13 | Morinaga Milk Industry Co., Ltd. | Culture containing a viable cell mass of Bifidobacteria and lactic acid bacteria |
IT1200625B (en) * | 1985-05-30 | 1989-01-27 | Sitia Yomo Spa | Immuno-stimulating compsn. |
EP0228881A2 (en) * | 1985-12-20 | 1987-07-15 | Roger A. Draft | Tank overfill valve |
US5143845A (en) * | 1986-09-03 | 1992-09-01 | Toa Pharmaceutical Co., Ltd. | Mixture of saccarifying lactic acid producing and butyric acid producing bacteria |
FR2609044A1 (en) * | 1986-12-30 | 1988-07-01 | Sperimentaledel Latte Centro | LACTIC FERMENTS IN SYMBIOTIC ASSOCIATION AND THEIR USE IN THE PREPARATION OF DAIRY, CHEESE AND FOOD PRODUCTS IN GENERAL |
US4913913A (en) * | 1987-02-25 | 1990-04-03 | The Calpis Food Industry Co., Ltd. | Method of preparation of bifidobacteria-containing fermented milk |
EP0291578A1 (en) * | 1987-05-20 | 1988-11-23 | Kopalnia Soli "Wieliczka" | Table salt enriched in bioelements |
US4806368A (en) * | 1987-09-16 | 1989-02-21 | Reddy Malireddy S | Shelf life and subsequent growth of lactobacillus acidophilus, propionibacterium shermanii and leuconostoc citrovorum in dietary fiber based supplement preparation |
US5128260A (en) * | 1989-01-12 | 1992-07-07 | Sanofi Bio Ingredients, Inc. | Process for preparing culture concentrates for direct vat set dairy products production |
US5108766A (en) * | 1990-10-22 | 1992-04-28 | Pierre Gelinas | Flavorants for enhancing the taste and flavor of bakery products and process of making |
US5219597A (en) * | 1991-02-20 | 1993-06-15 | Korea Food Research Institute | Method for producing highly concentrated, lactic-acid fermented product utilizing unground grainy rice and improving qualities thereof by the secondary, enzymatic treatment at fermentation |
US5474932A (en) * | 1991-07-25 | 1995-12-12 | Probi Ab | Intestine colonizing strains of lactobacilli |
Non-Patent Citations (20)
Title |
---|
A. Onderdonk et al, Obstetrics and Gynecology, "Quantitative and Qualitative Effects of Douche Preparation on Vaginal Microflora", 80, (1992), pp. 333-338. * |
Bifidobacteria microflora, vol. 1, No. 1, pp. 3-24, 1982, F. Mitsuoka, "Recent Trends in Research on Intestinal Flora". * |
Bifidobacteria Microflora, vol. 3, No. 1, pp. 29-33, 1984, T. * |
D. Triger, Journal of Hepatology, "Endotoxemia in Liver Disease-Time for Re-Appraisal?" 12, (1991), pp. 136-138. * |
Database WPI, Derwent Publications, AN-89-119459, Sep. 4, 1987, JP-A-1 066 124, Mar. 13, 1989. * |
Fernandes et al, FEMS Microbiology Reviews, "Therapeutic Role Dietary Lactobacilli and Lactobacillic Fermented Dairy Products" 46, (1987), pp. 343-356. * |
G. Kaklij et al, L Cancer Letters, "Antitumor Activity of Streptococcus thermophilus against Fibrosacoma: Role of T-cells", 56, (1991), pp. 37-43. * |
G. Molin et al, Antonie Van Leeuwenhoek, "Effect of Fermented Oatmeal Soup on the Cholesterol Level and the Lactobacillus Collonization of Rat Intestinal Mucosa", 61, (1992), pp. 167-173. * |
G.W. Elmer et al, JAMA, Vo. 275, pp. 870-876 (1996). * |
H. Goris et al, Microecology and Therapy, "Intestinal Flora Associated Endotoxin", 14, (1984), p. 267 (Abstract Only). * |
H. Kitazawa et al, Microbiol. Immunol., "Interferon Induction in Murine Peritoneal Macrophage by Stimulation with Lactobacillus acidophilus", 36, (1992), pp. 311-315. * |
H. Sawada et al, Agric. Biol. Chem., "Purification and Characterization of an Antihypertensive Compound from Lactobacillus casei", 54, pp. 3211-3219. * |
Kageyama, et al, The Effect of Bifidobacterium Administration in Patients with Leukemia. * |
M. Hall et al, Archives of Disease in Childhood, "Factors Influencing the Presence of Faecal bactobacilli in Early Infancy" 65, (1990), pp. 185-188. * |
Microecology and Therapy, vol. 14, pp. 109-126, 1984, Y. Kawai, "Effect of Cellular Extracts of Streptococci on Hyper-lipidemia in Rats, Rabbits, and Humans". * |
Microecology and Therapy, vol. 16, pp. 271-271, 1986, D. Muting, et al, "Bifidobacterium Bifidus Adminsitration in Humans: A Controlled Clinical Study in Liver cirrhosis". * |
N. Suegara, et al, "Hypolipidermic Effect of Streptococcus faecalis Kawai in Humans and Mechanisms of Serum Lipid Reduction", Microecology and therapy, vol. 15, pp. 271-280, 1985. * |
Patent Abstracts of Japan, vol. 9, No. 309 (C-318), Dec. 5, 1985, JP-A-60 149 527, Aug. 7, 1985. * |
S. Klebanoff et al, J. Exp. Med. "Viricidal Effect of Lactobacillus acidophilus on Human Immunodeficiency Virus Type 1: Possible Role in Heterosexual Transmission", 174, (1991), pp. 289-292. * |
S. Klebanoff et al, The Journal of Infectious Diseases, "Control of the Microbial Flora of the Vagina by Hydrogen Peroxide-Genrating Lactobacilli", 184, (1991), pp. 94-100. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41276E1 (en) * | 1996-03-11 | 2010-04-27 | Vsl Pharmaceuticals, Inc. | Strains of bacteria and pharmaceutical composition containing one or more of such strains and use of same for preventing and treating diseases associated with or caused by altered metabolism of bile acids |
US20110217368A1 (en) * | 2009-05-01 | 2011-09-08 | Satya Prakash | Bacterial compositions for prophylaxis and treatment of degenerative disease |
US10660857B2 (en) * | 2009-05-01 | 2020-05-26 | Uas Laboratories Llc | Bacterial compositions for prophylaxis and treatment of degenerative disease |
Also Published As
Publication number | Publication date |
---|---|
US5716615A (en) | 1998-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE40023E1 (en) | Dietary and pharmaceutical compositions containing lyophilized lactic bacteria, their preparation and use | |
EP0555618B1 (en) | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria | |
US11116806B2 (en) | Composite probiotic lactic acid bacteria powder and preparation method and use thereof | |
AU734194B2 (en) | Treatment of diarrhea | |
Pedrosa et al. | Survival of yogurt-containing organisms and Lactobacillus gasseri (ADH) and their effect on bacterial enzyme activity in the gastrointestinal tract of healthy and hypochlorhydric elderly subjects | |
US6596530B1 (en) | Strain of Lactobacillus gasseri | |
CN100386427C (en) | Bifidobacterium and products contg same | |
US7374753B1 (en) | Probiotic lactic acid bacterium to treat bacterial infections associated with SIDS | |
JPH0648979B2 (en) | Acidophilus strain culture, method for isolating the strain and method for treating the strain with bacteria | |
KR20050057259A (en) | Probiotic bacterium : lactobacillus fermentum | |
US11376289B2 (en) | Composition and uses thereof | |
CN101897729A (en) | Probiotic composition and preparation thereof | |
US20220211782A1 (en) | Composition for treatment, alleviation or prophylaxis of acne | |
JP2018532380A (en) | Enterobacteriaceae butyric acid intestini and uses thereof | |
JP2004051530A (en) | Intestinal flora-improving agent and food or drink containing the same | |
CN111494431B (en) | Application of probiotics in preparation of preparation for treating liver diseases | |
US20050215471A1 (en) | Compositions of bacteria and alpha-lactalbumin and uses thereof | |
CN112546074B (en) | Bifidobacterium breve capable of inhibiting release of IL-23 and Th17 axis-related inflammatory factors and application thereof | |
CN106974939B (en) | Application of probiotics of scleritis in treating and preventing obesity and related diseases | |
BG112471A (en) | Immunomodulating synbiotic composition | |
RU2104706C1 (en) | Method of bifido-containing preparation making | |
WO1999007393A1 (en) | Pharmaceutical product comprising bacterial strains for the colon therapy | |
RU2225438C2 (en) | Consortium of microorganisms mbi-4 consisting of bifidobacterium bifidum b-2, bifidobacterium infantis bi-7, bifidobacterium longum bl-5, bifidobacterium adolescentis mc-42 used for preparing fermented-milk foodstuffs | |
RU2083666C1 (en) | Method of preparing the dry bacterial preparation | |
BG2759U1 (en) | Immunomoduling synbiotic composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FPAY | Fee payment |
Year of fee payment: 12 |